Melanoma is the most aggressive form of skin cancer, driven by both genetic mutations and immune system interactions in the skin microenvironment. While visual inspection and biopsy remain standard, subtle molecular changes in immune activity often appear earlier, offering new opportunities for detection and treatment guidance.

The Skin Immunomelanoma Assay evaluates immune checkpoint activity, inflammatory signaling, and prometastatic biomarker patterns associated with melanoma. This test provides clinicians with a molecular-level perspective to support early diagnosis, precision treatment, and recurrence monitoring.

Why This Test Matters

Key Benefits

Standard scans can miss early immune and molecular changes. The Skin Immunomelanoma Assay detects these disruptions at the molecular level so patients and clinicians can act early.

Early Detection Support

Identifies immune-molecular patterns that precede visible melanoma progression.

Precision Therapy Guidance

Provides biomarker evidence for immunotherapy and targeted therapy selection.

Monitoring Capability

Tracks molecular changes during treatment and remission to support long-term care.

Complementary Value

Enhances dermatological evaluation and biopsy results with immune-based analysis.

Physician-Ready Report Included

Results in
10-14 days

Reliable Results You Can Trust

Biomarkers Assessed

The Skin Immunomelanoma Assay panel measures a targeted range of biomarkers to detect immune activity, tumor-promoting inflammation, and melanoma progression:

  • Immune checkpoint proteins (PD-L1, CTLA-4 pathways)

  • Tumor-promoting cytokines (IL-6, IL-8, TNF-α)

  • Angiogenesis markers (VEGF, FGF) driving melanoma spread

  • Melanoma-associated immune activity proteins

  • Prometastatic microenvironment signals

Download a Sample Report

How It Works

Process

From registration to results, the process is simple, secure, and stress-free. One blood draw gives you answers that imaging can’t.

01

Order & Registration

Patient registers through Persona Biomed’s secure portal.

02

Sample Collection

Blood draw performed at an approved lab or via mobile phlebotomy.

03

Laboratory Analysis

High-sensitivity assays measure immune and prometastatic biomarkers specific to melanoma.

04

Results Delivery

Comprehensive report provided in the patient portal, with physician-ready insights and AI-driven summaries for patients.

Who Should Consider This Test

who is this for

This test is intended for individuals who may be at risk, are experiencing related symptoms, or wish to take a proactive approach to their health, such as:

  • Individuals at high risk of melanoma (family history, fair skin, UV exposure).

  • Patients with suspicious or atypical moles and lesions.

  • Melanoma patients undergoing treatment requiring biomarker monitoring.

  • Survivors of melanoma needing recurrence surveillance.

Register Now for
Skin Immunomelanoma Assay

Register now for the Skin Immunomelanoma Assay to uncover hidden immune activity driving melanoma and guide proactive, precision treatment.

Register now